Glenmark Pharmaceuticals Limited — Updates, 21-01-2025: Press Release

Glenmark Pharmaceuticals Inc., USA has launched Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules, expanding its product portfolio within the institutional market. This product is bioequivalent and therapeutically equivalent to the reference listed drug by Hospira, Inc., which recorded annual sales of approximately $19.7 million in the U.S. market for the 12-month period ending November 2024. Marc Kikuchi, President & Business Head, North America, expressed enthusiasm about the launch, emphasizing Glenmark's dedication to providing quality and affordable alternatives for patients.

This development signifies a positive outlook for Glenmark as it enhances its presence in a competitive market segment, potentially driving growth. Investors may want to watch the market's response to this launch and its impact on Glenmark's revenue moving forward.